Dynamics and prognostic role of galectin-3 in patients with advanced heart failure, during left ventricular assist device support and following heart transplantation

Ellie Coromilas, Em-Claire Que-Xu, D’Vesharronne Moore, Tomoko S. Kato, Christina Wu, Ruiping Ji, Raymond Givens, Ulrich P. Jorde, Hiroo Takayama, Yoshifumi Naka, Isaac George, Donna Mancini and P. Christian Schulze

Abstract

Background: Galectin-3 is a marker of myocardial inflammation and fibrosis shown to correlate with morbidity and mortality in heart failure (HF). We examined the utility of galectin-3 as a marker of the severity of HF, the response of galectin-3 levels to ventricular assist device (LVAD) implantation or heart transplantation (HTx), and its use as a prognostic indicator.

Methods: Plasma galectin-3 was measured using a commercially available ELISA assay in patients with stable HF (n=55), severe HF (n=63), at 3 (n=17) and 6 (n=14) months post-LVAD and at LVAD explantation (n=23), patients following HTx (n=85) and healthy controls (n=30).

Results: Galectin-3 levels increase with the severity of HF (severe HF: 28.2 ± 14, stable HF: 19.7 ± 13, p = 0.001; controls: 13.2 ± 9 ng/ml, p = 0.02 versus stable HF). Following LVAD implantation, galectin-3 levels are initially lower (3 months: 23.7 ± 9, 6 months: 21.7 ± 9 versus 29.2 ± 14 ng/ml implantation; p = NS) but are higher at explantation (40.4 ± 19 ng/ml; p = 0.005 versus pre-LVAD). Galectin-3 levels >30 ng/ml are associated with lower survival post-LVAD placement (76.5 % versus 95.0 % at 2 years, p = 0.009). After HTx, galectin-3 levels are lower (17.8 ± 7.1 ng/ml post-HTx versus 28.2 ± 14 pre-HTx; p < 0.0001). Patients with coronary allograft vasculopathy (CAV) post-HTx showed higher galectin-3 levels (20.5 ± 8.8 ng/ml versus 16.8 ± 6.3, p = 0.1) and the degree of CAV correlated with levels of galectin-3 ($r^2 = 0.17, p < 0.0001$).

Conclusions: Galectin-3 is associated with the severity of HF, exhibits dynamic changes during mechanical unloading and predicts survival post-LVAD. Further, galectin-3 is associated with the development on CAV post-HTx. Galectin-3 might serve as a novel biomarker in patients with HF, during LVAD support and following HTx.

Keywords: Heart Failure, Galectin-3, LVAD, Heart Transplantation, Coronary Allograft Vasculopathy
Background

The syndrome of chronic heart failure (HF) is associated with increasing morbidity and mortality throughout the world. As the failing heart deteriorates in function, ventricular dilatation and hypertrophy compensate for increased wall stress associated with myocardial inflammation and cardiac fibrosis. Proliferating myofibroblasts deposit pro-collagen I into the myocardial matrix which is cross-linked to form collagen I [1–3]. Fibrotic remodeling and associated collagen deposition results in myocardial tissue heterogeneity and increased stiffness contributing to a vicious cycle of progressive cardiac dysfunction [2, 3].

Galectin-3, a paracrine factor secreted by macrophages, has been identified as a critical participant in the pathogenesis and progression of cardiac fibrosis and inflammation [2, 3]. Galectin-3 is secreted in response to mechanical stress and neurohormonal stimuli and potentiates TGF-β signaling, a critical regulator of cardiac fibrosis [2]. Therefore, galectin-3 is a particularly intriguing biomarker. Unlike current indicators of HF severity, it is directly implicated in the pathogenesis of cardiac fibrosis. Recent studies have shown that galectin-3 correlates with HF severity and may be predictive of clinical outcomes in HF patients [4–7].

Cardiac fibrosis directly correlates with the degree of ventricular dysfunction and dilatation as well as with myocardial wall stress. The impact of mechanical unloading through left ventricular assist device (LVAD) implantation on myocardial fibrosis is controversial and might be influenced by the type of LVAD implanted, underlying cardiomyopathy, and HF duration [8]. Nevertheless, LVAD implantation has evolved into a standard therapy for patients with advanced HF, serving either as destination therapy or as a “bridge-to-transplantation” [9]. Notably, restoration of cardiac output with LVADs has been shown to reverse cardiomyocyte hypertrophy and decrease ventricular end-diastolic dimensions [8, 10].

Interstitial myocardial fibrosis has also been linked to cardiac remodeling following heart transplantation (HTx) and in particular to the development of cardiac allograft vasculopathy (CAV). CAV is a largely immune-mediated process characterized by diffuse neo-intimal proliferation leading to coronary artery stenosis, which is a major cause of morbidity and mortality in patients following HTx with limited treatment options. Ten percent of HTx recipients are diagnosed with CAV 1 year post-HTx and more than 50 % have CAV by 10 years post-HTx [11].

We hypothesized that galectin-3 levels correlate with severity of HF and respond to mechanical unloading through LVAD placement. Therefore, we analyzed galectin-3 levels in patients with various degrees of HF, before and after mechanical unloading through LVAD implantation, and following HTx.

Methods

Study design and patient population

We included 118 patients with HF in this study. Fifty-five patients had stable HF defined as NYHA Class of I-IIIA. Sixty-three patients had severe HF (NYHA Class IIIB-IV), and 57 of these patients received LVADs either as a bridge-to-transplantation or destination therapy. Of the patients who received LVADs, 52 received a Heartmate II axial flow LVAD (Thoratec, Pleasanton, CA) and 5 received a Heartware centrifugal flow LVAD (Heartware, Framingham, MA). Follow-up samples were collected after device implantation (17 patients at 3 months post-LVAD and 14 patients at 6 months). Of the 57 patients who received LVADs, 14 had their LVADs explanted during HTx. Nine additional patients were recruited at the time of LVAD explantation, creating a LVAD-explantation cohort of 23 patients. In addition, 85 patients following HTx (1 month to 20 years post-HTx) were analyzed. All patients were evaluated for the presence of CAV by invasive coronary angiogram. CAV was defined according to the ISHLT CAV grading system. Twenty-three patients were diagnosed with CAV and 62 patients showed no sign of CAV. There were 30 healthy subjects who served as controls and were selected to match the age and gender of patients in the other cohorts. Patients with significant medical history, including but not limited to heart disease, lung disease, kidney disease, liver disease, cancer, stroke, diabetes, and thyroid disorders were excluded.

This is a retrospective study utilizing samples obtained from HF patients at Columbia University, some of whom underwent LVAD implantation or heart transplantation. All blood samples were immediately processed by centrifugation for collection of plasma and serum. Plasma was transferred to 1 mL cryotubes and stored at −80 °C until analysis. Clinical, laboratory, and outcome information was collected from patient medical records. All patients were recruited from the clinics or inpatient services at Columbia University Medical Center. The study protocol was approved by the Institutional Review Board at Columbia University Medical Center and written informed consent was obtained from all individuals prior to inclusion into the study.

Galectin-3 measurements

Plasma galectin-3 was measured using a commercially available ELISA assay (Galectin-3 Assay, BG Medicine, Waltham, MA), which has a measuring range of 1.4 to 94.8 ng/mL and coefficient of variation of 10.4 %, with no significant cross reactivity. Samples were run on a SpectraMax 250 microplate reader (Molecular Devices, Sunnyvale, CA). Calibration of the assay was performed according to the manufacturer’s recommendations and values were normalized to a standard curve.
Statistical analyses
Data were presented as mean ± standard deviation. Comparisons among all groups were performed using ANOVA or Student’s t-test as appropriate, as well as correlational analysis using Spearman’s correlation. ROC analysis was used to identify galectin-3 levels predictive of poor outcome and event rates were calculated using the Kaplan-Meier method. Probability values of $p < 0.05$ were considered to be statistically significant.

Results
Galectin-3 levels in patients with different degrees of heart Failure
Galectin-3 levels were measured in 55 patients with stable HF (defined as NYHA Class I-IIIA), 63 patients with severe HF (NYHA Class IIIB-IV) and 30 healthy controls. Baseline demographics are listed in Table 1. Patients with severe HF had lower LVEF and higher BNP levels compared to those with stable HF. Patients with severe HF were also less likely to be hypertensive, and more likely to have concurrent kidney disease.

Patients with stable HF had higher galectin-3 levels compared to healthy controls (19.7 ± 13 versus 13.2 ± 9 ng/ml; $p = 0.02$). Galectin-3 levels were higher in patients with severe HF compared to patients with stable HF (28.2 ± 14 ng/ml in severe HF; $p = 0.001$) (Fig. 1a).

Galectin-3 levels correlated with severity of HF as defined by NYHA class ($p = 0.001$) and creatinine ($R^2 = 0.166; p < 0.0001$) (Fig. 1b). There was no correlation between galectin-3 levels and BNP ($R^2 = 0.032; p = 0.09$) or LVEF ($R^2 = 0.0095; p = 0.30$) (Fig. 1c-d)

Dynamics of galectin-3 levels following LVAD implantation
Of the 57 patients who received LVADs, 17 patients had follow-up levels measured at 3-months, 14 patients had

---

Table 1 Demographic data of patients with HF

|                         | Controls (n = 30) | Stable HF (n = 55) | p-value* | Severe HF (n = 63) | p-value† |
|-------------------------|------------------|-------------------|----------|-------------------|---------|
| Galectin-3 (ng/ml)      | 13.2 ± 9         | 19.7 ± 13         | 0.02     | 28.2 ± 14         | 0.001   |
| Age (yrs)               | 52 ± 8           | 59 ± 10           | 0.001    | 62 ± 11           | NS      |
| Gender (% male)         | 73 %             | 76 %              | NS       | 92 %              | 0.01    |
| BMI (kg/m²)             | 27 ± 5           | 28 ± 4            | NS       | 28 ± 5            | NS      |
| Etiology (%)            | -                | 45 %              | -        | 56 %              | NS      |
| Ischemic                | -                | 45 %              | -        | 56 %              | NS      |
| Dilated                 | -                | 42 %              | -        | 40 %              | NS      |
| Hypertrophy             | -                | 2 %               | -        | 1 %               | NS      |
| Unspecified             | -                | 11 %              | -        | 3 %               | NS      |
| NYHA Class              | -                | 2.3 ± 0.8         | -        | 3.7 ± 0.4         | <0.0001 |
| LVEF (%)                | -                | 24 ± 9            | -        | 18 ± 5            | <0.0001 |
| BNP (ng/mol)            | -                | 707 ± 762         | -        | 1384 ± 1097       | 0.001   |
| Comorbidities           |                  |                   |          |                   |         |
| Hypertension            | 13.3 %           | 61.8 %            | <0.0001  | 49.2 %            | 0.007   |
| Previous MI*            | 0 %              | 41.8 %            | <0.0001  | 38.1 %            | NS      |
| Hyperlipidemia          | 23.3 %           | 50.9 %            | 0.0005   | 41.2 %            | NS      |
| Diabetes                | 0 %              | 30.9 %            | 0.0001   | 39.7 %            | NS      |
| Kidney Disease          | 0 %              | 12.7 %            | 0.02     | 38.1 %            | 0.007   |
| COPD*                   | 0 %              | 9.1 %             | 0.04     | 14.3 %            | NS      |
| Smoker                  | 6.7 %            | 5.5 %             | NS       | 1.6 %             | NS      |
| Lab Values              |                  |                   |          |                   |         |
| WBC* (x10³/µL)          | -                | 7.1 ± 2           | -        | 8.8 ± 3           | 0.001   |
| Hct* (g/dL)             | -                | 39 ± 4            | -        | 32 ± 10           | <0.0001 |
| Na* (mEq/L)             | 145 ± 10         | 137 ± 3           | <0.0001  | 135 ± 3           | 0.0008  |
| Creat* (mg/dL)          | 1.0 ± 0.3        | 1.3 ± 0.9         | NS       | 1.5 ± 0.5         | NS      |
| T-Bil** (mg/dL)         | 0.5 ± 0.2        | 0.7 ± 0.4         | 0.007    | 1.6 ± 1.4         | 0.0004  |
| Albumin (g/dL)          | 4.9 ± 0.4        | 4.3 ± 0.4         | <0.0001  | 3.6 ± 0.5         | <0.0001 |

* p value versus Controls † p value versus Stable HF
*M myocardial infarction, *COPD chronic obstructive pulmonary disease, *WBC white blood count, *Hct hematocrit, *Na sodium, *Creat creatinine, *T-Bil total bilirubin
follow-up levels measured at 6-months and 14 patients had levels measured at the time of LVAD explantation. An additional 9 patients were analyzed at the time of explantation. On average, patients who underwent LVAD explantation had been on LVAD support for 277 ± 223 days. Demographic information of this cohort at baseline and during follow-up is listed in Table 2.

Hemodynamic unloading was associated with lower BNP levels following LVAD treatment (1378 ± 1084 versus 737 ± 470 pmol/L at explant, p = 0.01). Further, LVAD support was associated with improvement in echocardiographic parameters with a smaller left ventricular end-diastolic diameter (LVEDD) and left atrial (LA) diameter (LVEDD: 67.2 ± 10 versus 58.4 ± 10 mm at explant, p = 0.012; LA: 50.1 ± 60 versus 44.3 ± 70 mm at explant, p = 0.004). There was also a trend towards smaller left ventricular end systolic diameter (LVESD: 60.8 ± 11 versus 52.8 ± 14 mm, p = 0.1). There was no significant change in aortic root diameter (3.4 ± 0.4 vs. 3.5 ± 0.3 cm; p = 0.39).

Following LVAD implantation, a downward trend in galectin-3 levels was noted, although it did not reach significance (29.2 ± 14 ng/ml at implantation versus 23.7 ± 8 ng/ml 3 months post-implantation; p = 0.13) (Fig. 2a). Six months post-implantation, the average galectin-3 level was 21.7 ± 9 ng/ml (versus 29.2 ± 14 ng/ml at implantation, p = 0.06). Of the 17 patients who were evaluated 3 months following implantation, 64.7 % had lower galectin-3 levels compared to implantation. For these 17 patients, the mean galectin-3 level was lower at 3 months, though this difference was not significant (23.7 ± 8 at 3 months versus 29.0 ± 14.5 ng/ml at implantation, p = 0.2). Of the 14 patients who were evaluated at 6 months, 57.1 % had lower galectin-3 levels compared to implantation. Again, the mean was lower at 6 months for these patients than at the time of implantation (21.7 ± 9 ng/ml at 6 months versus 28.1 ± 15 ng/ml at implantation, p = 0.18).

Surprisingly, galectin-3 levels were significantly higher at the time of LVAD explantation (40.4 ± 19 at explant versus 29.2 ± 14 ng/ml at the time of implantation, p = 0.005). Of the 23 explanted patients, 14 patients were evaluated both at implantation and explantation, allowing for direct comparison of values. Of these 14 patients, 13 (92.9 %) had elevated galectin-3 levels at the time of explantation as compared to time of implantation (Fig. 2b). Galectin-3 was significantly higher at the time of explantation compared to implantation in these 14 patients. (40.6 ± 17 versus 20.8 ± 5 ng/ml, p = 0.0002).

**Prognostic impact of galectin-3 levels on clinical outcomes**

Patients with severe HF who died during the study had significantly higher galectin-3 levels than those who were still alive (48.6 ± 16 versus 28.2 ± 14 ng/ml, p = 0.02).
Table 2: Demographic data of patients undergoing LVAD placement

|                      | LVAD Implant (n = 57) | 3 Months Post-LVAD (n = 17) | p-value* | 6 Months Post-LVAD (n = 14) | p-value* | LVAD Explant (n = 23) | p-value* |
|----------------------|-----------------------|-----------------------------|----------|-----------------------------|----------|-----------------------|----------|
| Galectin-3 (ng/ml)   | 29.2 ± 14             | 23.7 ± 8                    | NS       | 21.7 ± 9                    | NS       | 40.4 ± 19             | 0.005    |
| Age (yrs)            | 63 ± 10               | 65 ± 9                      | NS       | 60 ± 12                     | NS       | 63 ± 8                | NS       |
| Gender (% male)      | 91 %                  | 100 %                       | NS       | 93 %                        | NS       | 87 %                  | NS       |
| BMI (kg/m²)          | 28 ± 5                | 28 ± 4                      | NS       | 28 ± 5                      | NS       | 26 ± 4                | NS       |
| Etiology (%)         |                       |                             |          |                             |          |                       |          |
| Ischemic             | 56 %                  | 65 %                        | NS       | 64 %                        | NS       | 65 %                  | NS       |
| Dilated              | 39 %                  | 35 %                        | NS       | 36 %                        | NS       | 35 %                  | NS       |
| Hypertrophy          | 2 %                   | 0 %                         | NS       | 0 %                         | NS       | 0 %                   | NS       |
| Unspecified          | 3 %                   | 0 %                         | NS       | 0 %                         | NS       | 0 %                   | NS       |
| BNP (ng/mol)         | 1378 ± 1084           | -                           | -        | 737 ± 470                   | 0.01     |
| LVAD Type (%)        |                       |                             |          |                             |          |                       |          |
| Continuous           | 91 %                  | 100 %                       | NS       | 82 %                        | NS       | 100 %                 | NS       |
| Pulsatile            | 9 %                   | 0 %                         | NS       | 18 %                        | NS       | 0 %                   | NS       |
| Comorbidities        |                       |                             |          |                             |          |                       |          |
| Hypertension         | 54.4 %                | 64.7 %                      | NS       | 42.9 %                      | NS       | 47.8 %                | NS       |
| Previous MI          | 42.1 %                | 47.1 %                      | NS       | 35.7 %                      | NS       | 52.2 %                | NS       |
| Hyperlipidemia       | 45.6 %                | 52.9 %                      | NS       | 42.9 %                      | NS       | 47.8 %                | NS       |
| Diabetes             | 39.7 %                | 52.9 %                      | NS       | 21.4 %                      | NS       | 30.4 %                | NS       |
| Kidney Disease       | 38.1 %                | 64.7 %                      | NS       | 35.7 %                      | NS       | 43.5 %                | NS       |
| COPD                 | 15.8 %                | 29.4 %                      | NS       | 7.1 %                       | NS       | 17.4 %                | NS       |
| Smoker               | 1.8 %                 | 0 %                         | NS       | 0 %                         | NS       | 4.4 %                 | NS       |
| Lab Values           |                       |                             |          |                             |          |                       |          |
| WBCc (x10⁹/μL)       | 9.0 ± 3               | 9.4 ± 4                     | NS       | 8.9 ± 4                     | NS       | 9.3 ± 4               | NS       |
| Hctd (g/dL)          | 31 ± 10               | 32 ± 9                      | NS       | 35 ± 7                      | NS       | 30 ± 4                | NS       |
| Na* (mEq/L)          | 136 ± 4               | 136 ± 4                     | NS       | 135 ± 4                     | NS       | 137 ± 4               | NS       |
| Crea* (mg/dL)        | 1.5 ± 0.5             | 1.6 ± 0.4                   | NS       | 1.4 ± 0.5                   | NS       | 1.3 ± 0.6             | NS       |
| T-Bili (mg/dL)       | 1.6 ± 1.4             | 1.3 ± 0.4                   | NS       | 1.5 ± 1.7                   | NS       | 1.2 ± 0.9             | NS       |
| Albumin (g/dL)       | 3.6 ± 0.5             | 3.5 ± 0.5                   | NS       | 3.8 ± 0.4                   | NS       | 3.3 ± 0.5             | 0.02     |

*p value versus LVAD Implant

*M myocardial infarction, *COPD chronic obstructive pulmonary disease, *WBC white blood count, *Hct hematocrit, *Na sodium, *Crea creatinine, *T-Bili total bilirubin

Fig. 2: Changes in galectin-3 levels following LVAD implantation. a Galectin-3 levels show a trend towards lower levels early after LVAD placement at 3 and 6 months but were higher in patients at the time of LVAD explantation (**p < 0.01). b Dynamics of 14 paired patient samples time of implantation to time of explantation.
determine if galectin-3 could be used as a prognostic indicator in this cohort, we performed an ROC curve analysis of patients with severe HF and determined that a pre-operative galectin-3 cutoff value of 35.4 ng/ml predicted higher mortality following LVAD placement (66.7 % specificity, 84.2 % sensitivity, \( p = 0.025 \)) (Fig. 3a). Given this, we chose a clinically useful cutoff of 30 ng/ml and dichotomized patients based on this level. Galectin-3 levels greater than 30 ng/ml at the time of LVAD implantation are associated with poor survival at 2 years post implantation (\( p = 0.009 \)) (Fig. 3b). 2 years following implantation, 95.0 % of patients with galectin-3 levels <30 ng/ml at the time of LVAD implantation were still alive, compared to 76.5 % of patients with galectin-3 levels >30 ng/ml at implantation.

**Galectin-3 levels decrease following heart transplantation**

We analyzed galectin-3 levels in 85 patients following HTx (1 month-20 years post-HTx, Table 3). On average, galectin-3 levels were measured 5.4 ± 0.64 years post-HTx. Galectin-3 levels were lower following HTx compared to in patients with severe HF (17.8 ± 7.3 post-HTx versus 28.2 ± 14 ng/ml in severe HF, \( p < 0.0001 \)) (Fig. 4a). However, galectin-3 levels post-HTx were found to be higher compared to healthy controls (17.8 ± 7.3 versus 13.2 ± 9.4 ng/ml in controls, \( p = 0.002 \)) and comparable to levels in patients with stable HF (19.7 ± 13.0 ng/ml in stable HF, \( p = 0.44 \)). No correlation was found between galectin levels and time since HTx.

Patients following HTx were sub-classified with regard to the occurrence of CAV according to the ISHLT CAV grading system (CAV Grade 0: \( n = 62 \), Grade 1–3: \( n = 23 \)). Galectin-3 levels were higher in patients with evidence of CAV compared to those without CAV (20.5 ± 8.9 versus 16.8 ± 6.3 ng/mL without CAV, \( p = 0.03 \)) (Fig. 4b). Spearman correlational analysis revealed a correlation between galectin-3 levels and the occurrence of CAV (\( r^2 = 0.17, p < 0.0001 \)).

**Discussion**

In this study, we measured galectin-3 levels in patients with various stages of HF, following LVAD support, and after HTx. Galectin-3 was higher in advanced stages of HF compared to controls, was lower post-LVAD, but increased at the time of LVAD explantation. Baseline galectin-3 greater than 30 ng/mL predicted poor outcome following LVAD placement. Patients following HTx on average have lower galectin-3 levels, but levels are higher in the presence of CAV.

Interest in galectin-3 as a potential marker of the severity and outcome of HF has increased with evidence that it is involved in the pathogenesis of cardiac fibrosis and HF progression. By stimulating TGF-β, galectin-3 potentiates collagen deposition and extracellular matrix turnover, leading to an increased proportion of stiffer collagen I in the failing myocardium [12–14]. Prior studies have identified galectin-3 as the most robustly up-regulated protein in models of cardiac hypertrophy and left ventricular dysfunction, and mice with a galectin-3 gene deletion develop myocardial hypertrophy without cardiac dysfunction and fibrosis [5, 15]. Consistent with these animal models, galectin-3 levels have consistently been shown to correlate with disease severity and NYHA class in HF [3, 6, 7].

Our results confirmed that galectin-3 levels correlated with the severity of HF, and levels in healthy subjects were
consistent with prior reports defining the normal range as less than 18 ng/ml [7]. Although BNP and LVEF are often used to measure HF severity, we found that galectin-3 levels were not directly associated with these parameters, though some prior studies have shown correlation between galectin-3 and these measures. [16]. Because the majority of HF patients in our study had ischemic HF, our results should only be applied to this population, although others have shown comparable levels of galectin-3 in patients with ischemic and non-ischemic HF [5].

![Fig. 4 Changes in galectin-3 levels following HTx.](image)

**Table 3** Demographic data of patients following HTx

|                        | Control (n = 30) | Post-HTx (n = 85) | p-value* | No CAV (n = 62) | CAV (n = 23) | p-value† |
|------------------------|------------------|-------------------|----------|-----------------|-------------|---------|
| Galectin-3 (ng/ml)    | 13.2 ± 9         | 17.8 ± 7          | 0.002    | 16.8 ± 6        | 20.5 ± 9    | 0.03    |
| Age (yrs)             | 52 ± 8           | 55 ± 14           | NS       | 54 ± 14         | 58 ± 13     | NS      |
| Gender (% male)       | 73 %             | 71 %              | NS       | 80 %            | 81 %        | 0.02    |
| BMI (kg/m²)           | 27 ± 5           | 29 ± 6            | NS       | 29 ± 6          | 28 ± 5      | NS      |
| Etiology (%)          |                  |                   |          |                 |             |         |
| Ischemic              | -                | 32 %              | 0.002    | 54 %            | 45 %         | NS      |
| Dilated               | -                | 43 %              |          | 31 %            | 45 %         | NS      |
| Hypertrophy           | -                | 2 %               | 0.02     | 0 %             | 3 %          | NS      |
| Unspecified           | -                | 13 %              |          | 15 %            | 7 %          | NS      |
| LVEF (%)              | -                | 39 ± 8            |          | 60 ± 8          | 55 ± 8      | <0.0001 |
| Years post-HTx        | -                | 5.4 ± 0.6         | <0.0001  | 5.2 ± 1.2       | 5.5 ± 1.0   | NS      |
| Comorbidities         |                  |                   |          |                 |             |         |
| Hypertension          | 13.3 %           | 61.7 %            | <0.0001  | 55.6 %          | 67.7 %      | NS      |
| Prior MI**            | 0 %              | 32.6 %            | 0.0003   | 25.9 %          | 45.2 %      | NS      |
| Hyperlipidemia        | 23.3 %           | 48.3 %            | 0.02     | 50.0 %          | 45.2 %      | NS      |
| Diabetes              | 0 %              | 49.4 %            | <0.0001  | 50.0 %          | 41.9 %      | NS      |
| Kidney Disease        | 0 %              | 38.2 %            | <0.0001  | 31.5 %          | 48.4 %      | NS      |
| COPD†                 | 0 %              | 6.7 %             | NS       | 7.4 %           | 3.2 %       | NS      |
| Smoker                | 6.7 %            | 5.6 %             | NS       | 7.4 %           | 3.2 %       | NS      |
| Lab Values            |                  |                   |          |                 |             |         |
| WBC (x10³/μL)         | 7.6 ± 5          | 6.8 ± 2.3         | NS       | 6.9 ± 2.2       | 6.6 ± 2.6   | NS      |
| Na (mEq/L)            | 145 ± 10         | 139 ± 2           | <0.0001  | 139 ± 2         | 140 ± 2     | NS      |
| Crea (mg/dL)          | 1.0 ± 0.3        | 1.5 ± 0.6         | <0.0001  | 1.5 ± 0.5       | 1.7 ± 0.6   | NS      |
| T-Bili (mg/dL)        | 0.5 ± 0.2        | 0.7 ± 0.4         | 0.01     | 0.7 ± 0.3       | 0.8 ± 0.4   | NS      |
| Albumin (g/dL)        | 4.9 ± 0.4        | 4.3 ± 0.4         | <0.0001  | 4.3 ± 0.4       | 4.2 ± 0.5   | 0.05    |

* p value versus controls; †p value versus no CAV

**MI** myocardial infarction, **COPD** chronic obstructive pulmonary disease, **WBC** white blood count, **Na** sodium, **Crea** creatinine; **T-Bili** total bilirubin The table above shows the demographic data of patients following HTx. The changes in galectin-3 levels following HTx are depicted in Fig. 4.
Galecin-3 levels with LVAD support
That galecin-3 levels may initially decrease after LVAD implantation but were significantly increased at explantation offers interesting insight into the pathologic changes that occur with mechanical support. Evidence regarding changes in fibrosis following LVAD implantation have been conflicting [17]. Our group previously demonstrated decreased ECM turnover with reduced levels of circulating and myocardial metalloproteinases following LVAD placement [18]. Similarly, others have shown decreased myocardial collagen content in LVAD-supported patients [19, 20]. However, others have shown an increase in collagen deposition and an associated increase in myocardial stiffness [10, 21, 22].

Only one recent study analyzed changes in galecin-3 levels in patients undergoing LVAD implantation. Milt ing et al. found that 30 days post-implantation, ECM turnover defined by changes in levels of matrix metalloproteinases and their tissue inhibitors increased, but galecin-3 levels remained the same [23]. Our average length of LVAD treatment of 277 days is longer than in the study by Milt ing et al., which may explain why we were able to detect an increase in galecin-3 levels.

The dynamics of galecin-3 levels following LVAD implantation may be indicative of the complicated changes in myocardial structure and fibrosis, and further studies are necessary to more clearly elucidate these fluctuations in galecin-3 levels. Because galecin-3 is secreted in response to mechanical stress, decreased expression shortly after device implantation may be explained by ventricular unloading. However, elevated levels at explantation may indicate that prolonged mechanical support leads to an increase in inflammation and cardiac fibrosis. This is consistent with the results of Maybaum et al., who found that although LVEF significantly improved after LVAD implantation in almost all patients, longer duration of LVAD support appeared to deleteriously affect LV function [24]. Pathologic studies should be conducted to correlate galecin-3 levels with the amount of fibrosis as well as cardiac macrophage content and activation. The specific signals for increasing fibrosis after LVAD placement have not yet been fully elucidated, but the identification and reversal of this pro-fibrotic signal could assist to better define the potential of temporary LVAD placement as a “bridge to recovery” intervention in certain patients with advanced HF.

Adding to the value of galecin-3 is its potential use as a predictor of poor outcome in patients with HF. Van Kimmenade et al. found galecin-3 levels to be prognostic of adverse outcomes over 60 days [5]. Galecin-3 has also been shown to be an independent predictor of mortality in patients with NYHA class III-IV HF and in the general population, with levels >25.9 ng/ml shown to be predictive of a rapid progression of HF [3, 6, 7]. Adding to these findings, galecin-3 levels were predictive of survival in our cohort of patients undergoing LVAD placement, with plasma levels greater than 30 ng/ml at the time of implantation associated with greater mortality. Of note, although patients with galecin-3 levels >30 ng/ml were of similar age, NYHA Class, and had similar duration of HF and BNP levels than those with galecin-3 levels <30 ng/ml, patients with higher galecin-3 levels did have higher creatinine levels. It is possible, therefore, that some of the increased risk seen was due to impaired renal function. However, another study found that levels were a univariate but not independent risk factor for death in patients undergoing LVAD implantation [25]. These results indicate that this predictive value may be applicable to the subset of HF patients undergoing LVAD implantation, providing important prognostic information that may be used for patient selection and for stratifying high-risk patients.

Galecin-3 levels following heart transplantation
We found that following HTx, the average galecin-3 level was significantly lower than in patients with severe HF. This decrease was expected with the replacement of the failing heart, but notably galecin-3 values did not return to normal levels; galecin-3 levels in transplanted patients were comparable to levels in patients with stable HF. Higher galecin-3 levels post-HTx might be related to cardiomyocyte hypertrophy and myocardial fibrosis after HTx but, of note, elevated galecin-3 levels are not related to the time period since HTx. No other study has analyzed trends in galecin-3 levels following HTx, but prior studies have shown that fibrosis increases within 2 months after HTx with little change over the subsequent 5–6 years [26]. Another explanation for dynamics in galecin-3 levels following HTx may be the use of anti-inflammatory agents to prevent rejection; as galecin-3 is an inflammatory factor released by macrophages, and its expression may be modified by this external variable.

As many as half of transplant patients will show angiographic evidence of CAV 5–15 years after HTx, accounting for 30–50 % of late graft attrition [27, 28]. Given this high prevalence and mortality, identification of CAV is important. However, diagnosis is limited by the lack of clinical symptoms of ischemia in the denervated allograft as well as limitations inherent in coronary angiography, which is a relatively insensitive study and frequently underestimates the severity and presence of CAV [29].

CAV is characterized by intimal luminal narrowing due to a fibrotic process, with a high expression of TGF-β and macrophage markers in the intima [30]. T-cells and macrophages have been shown to modulate the pathogenesis of CAV with a specific role for macrophages regulating the fibrotic response, and vascular fibrosis after HTx has been associated with more severe CAV and poor event-free survival rates [31].
Our analysis revealed a significant difference in galectin-3 levels between patients with and without CAV, and higher levels in patients with more severe degrees of CAV. Given the importance of fibrosis in CAV pathogenesis and the implication of macrophages in its development, galectin-3 may serve as a useful marker of CAV severity of. Further studies are necessary to better elucidate whether or not galectin-3 could be used as a screening tool in the diagnosis of CAV in high-risk patients, potentially linking this novel biomarker to active fibrotic processes and signaling in the cardiac allograft.

Of note, our study is limited by its retrospective observational nature with a limited number of patients from a single center. Larger, prospective studies should be done to better elucidate the value of galectin-3 as a predictive biomarker and its ability to stratify risk in HF patients, and future studies would benefit from including pathologic analysis in addition to serologic. Additionally, not all of the LVAD patients had consistent follow-up and 14 of the patients in the explant cohort did not have implant values available, which may have affected the results of the study and may represent a bias towards patients feeling well enough to come to the study visit. The small number of patients also limited our ability to correct for confounders such as age, and renal function when assessing the predictive value of galectin-3. We do not have baseline pre-HTx values for patients in the transplant cohort, limiting the direct comparison to the severe HF cohort. Additionally there are a relatively small number of patients in the CAV subgroups of post-HTx patients.

**Conclusions**

Our results indicate that galectin-3 may serve as a useful biomarker for evaluating the severity and outcomes in HF and in patients undergoing LVAD implantation. Galectin-3 is an intriguing biomarker due to its relation to cardiac inflammation and fibrosis and, unlike BNP levels, galectin-3 values are not drastically changed by acute cardiac volume or pressure overload. Its role in patients following HTx needs further analysis in larger studies.

**Abbreviations**

HF, heart failure; LVAD, left ventricular assist device; HTx, heart transplantation; CAV, coronary allograft vasculopathy; LVEDD, left ventricular end-diastolic diameter; LA, left atrial

**Funding**

This work was supported by grants from the NIH Heart, Lung and Blood Institute (HL105742-01, P30 HL101272-01, UL1 RR 024156, HL073029) and the Herbert and Florence Irving Scholar Award to Dr. Schulze, as well as the NIH Ruth L. Kirschstein National Research Service Award Short-Term Research Training Grant to Ellie Corimilas.

**Availability of data and materials**

The data supporting the findings of this study can be shared prior to publication of the manuscript.

**Author’s contributions**

EC participated in conception and design, ran ELISA assays, participated in the acquisition, analysis, and interpretation of data, and drafting of the manuscript. EQ participated in data acquisition and interpretation of data and participated in critical revision of the manuscript. DM participated in data acquisition and critical revision of the manuscript. TK read echocardiograms, performed statistical analysis, and participated in critical review of the manuscript. CW participated in data acquisition and critical revision of the manuscript. RJ participated in data acquisition, interpretation of data, and critical revision of the manuscript. RG participated in critical evaluation of the manuscript. UJ participated in critical revision of manuscript. HT participated in data collection and critical revision of manuscript. YN participated in data collection and critical revision of the manuscript. IG participated in data collection and critical revision of the manuscript. IG participated in data collection and critical revision of the manuscript. DM participated in critical revision of the manuscript. PCS participated in conception and design, interpretation and analysis of data, and drafting of manuscript. All authors read and approved the final manuscript.

**Competing interests**

The authors declare that they have no competing interests.

**Consent for publication**

This manuscript does not include any individual person’s data.

**Ethics approval and consent to participate**

This research was approved by the Columbia University IRB. All participants signed an informed consent to participate in this research.

**Author details**

1. Department of Medicine, Division of Cardiology, Columbia University Medical Center, 166 Fort Washington Avenue, New York, NY 10032, USA.
2. Division of Cardiothoracic Surgery, Department of Surgery, Columbia University Medical Center, 166 Fort Washington Avenue, New York, NY 10032, USA.
3. Department of Medicine, Division of Cardiology, Angiology, Pneumology and Intensive Medical Care, Friedrich-Schiller-University Jena, Erlanger Allee 101, 07743 Jena, Germany.

**Received:** 2 March 2016 **Accepted:** 23 May 2016

**Published online:** 14 June 2016

**References**

1. Westermann D, Lindner D, Kaiser M, Zietzch C, Savvatis K, Escher F, von Schlippenbach J, Skurk C, Steendijk P, Radj A, et al. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Heart Fail. 2011;4(1):44–52.
2. Henderson NC, Sethi T. The regulation of inflammation by galectin-3. Immunol Rev. 2009;223(1):60–71.
3. McCullough PA, Oldobateke A, Vanhecke TE. Galectin-3: a novel blood test for the evaluation and management of patients with heart failure. Rev Cardiovasc Med. 2011;12(4):200–10.
4. Sharma UC, Pokharel S, van Brekel TJ, van Berlo JH, Cleutjens JP, Schooen B, Andre S, Crijns HJ, Gabius HJ, Maessen J, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004;109(13):121–8.
5. van Kimmenade RR, Januzij JR, Ellinor PT, Sharma UC, Bakker JA, Low AF, Martinez A, Crijns HJ, MacRae CA, Mengeheer PP, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol. 2006;48(6):1217–24.
6. Lok DJ, Van Der Meer P, de la Porte PW, Lipsic E, Van Wijngaarden J, Hillege HL, van Veldhuisen DJ. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol. 2010;99(3):323–8.
7. de Boer RA, van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC, van Gilst WH, Hillege HL, Bakker SJ, van der Harst P. The fibrosis marker galectin-3 and outcome in the general population. J Intern Med. 2012;271(1):55–64.
8. Drakos SG, Kfouri AG, Selzman CH, Verna DR, Nanas JN, Li DY, Stehlik J. Left ventricular assist device unloading effects on myocardial structure and function: current status of the field and call for action. Curr Opin Cardiol. 2011;26(3):245–55.
9. Kato TS, Farr M, Schulze PC, Maurer M, Shahzad K, Ivata S, Homma S, Jorde U, Takayama H, Naka Y, et al. Usefulness of two-dimensional echocardiographic parameters of the left side of the heart to predict right ventricular failure after left ventricular assist device implantation. Am J Cardiol. 2012;109(2):246–51.

10. Klotz S, Forony RJ, Dickstein ML, Gu A, Garelds IM, Danser AH, Oz MC, D’Armiento J, Burkhoff D. Mechanical unloading during left ventricular assist device support increases left ventricular collagen cross-linking and myocardial stiffness. Circulation. 2005;112(3):364–74.

11. Stehlik J, Edwards LB, Kuchenyayava AY, Benden C, Christie JD, Dipchand AI, Dobbs L, Kirk R, Rahmeln AO, Hertz ML, et al. The registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report—2012. J Heart Lung Transplant. 2012;31(10):1052–64.

12. Weber KT. Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation. 1997;96(1):4065–82.

13. Biolo A, Fisch M, Balog J, Chao T, Schulze PC, Ooi H, Siwik D, Colucci WS. Episodes of acute heart failure syndrome are associated with increased levels of troponin and extracellular matrix markers. Circ Heart Fail. 2010;3(1):44–50.

14. Lin YH, Lin LY, Wu YW, Chien RL, Lee CM, Hsu RB, Chao CL, Wang SS, Heilin YC, Liao LC, et al. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clinica chimica acta: international journal of clinical chemistry. 2009;409(1–2):196–9.

15. Yu L, Ruffred WP, Meissner M, Bos EM, van Goor H, Sanjabi B, van der Harst P, Pitt B, Goldstein IU, Koerts JA, et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail. 2013;6(1):107–17.

16. Felker GM, Fluzat M, Shaw UK, Clare R, Whellan DJ, Bettan L, Shielor SC, Donahue M, Kitzman DW, Zannad F, et al. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail. 2012;5(1):72–8.

17. Li YY, Feng Y, McTieren CF, Pei W, Moravec DB, Wang P, Rosenblum W, Komros RL, Feldman AM. Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices. Circulation. 2001;104(10):1147–52.

18. Kato TS, Chokshi A, Singh P, Khawaja T, Ivata S, Homma S, Akashi H, Cheema F, Yang J, Takayama H, et al. Markers of extracellular matrix turnover and the development of right ventricular failure after ventricular assist device implantation in patients with advanced heart failure. J Heart Lung Transplant. 2012;31(1):37–45.

19. Bruckner BA, Stetson SJ, Perez-Verdia A, Youker KA, Radovancevic B, Connelly JH, Koemer MM, Entman ME, Frazier OH, Noon GP, et al. Regression of fibrosis and hypertrophy in failing myocardium following mechanical circulatory support. J Heart Lung Transplant. 2001;20(4):457–64.

20. Thompson LO, Skrabal CA, Loebe M, Lafuente JA, Roberts RR, Akul J, Jones V, Bruckner BA, Thohan V, Noon GP, et al. Plasma neurohormone levels correlate with left ventricular functional and morphological improvement in LVAD patients. J Surg Res. 2005;125(1):25–32.

21. Scheinin SA, Capek P, Radovancevic B, Duncan JM, McAllister Jr HA, Frazier OH. The effect of prolonged left ventricular support on myocardial histopathology in patients with end-stage cardiomyopathy. ASAIO J. 1992;38(3):M271–4.

22. McCarthy PM, Nakatani S, Vargo R, Kottke-Marchant K, Margulies K, McRee S, Frazier OH, et al. Cardiac improvement during mechanical circulatory support: a prospective multicenter study of the LVAD Working Group. Circulation. 2007;115(19):2497–505.

23. Milting H, Ellingham P, Seewald M, Coker H, Bohms B, Kostuk WJ, Villén CP, Collard L, Ferron P, Seewald M, et al. Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant. 2008;27(6):589–96.

24. Maybaum S, Mancini D, Yxdas S, Starling RC, Aaronson K, Pagani FD, Miller LW, Margulies K, McRee S, Frazier OH, et al. Cardiac improvement during mechanical circulatory support: a prospective multicenter study of the LVAD Working Group. Circulation. 2007;115(19):2497–505.

25. Erkilet G, Ozpeker C, Bothig D, Kramer F, Rofe D, Bohms B, Morshuis M, Gumert J, Milting H. The biomarker plasma galectin-3 in advanced heart failure and survival with mechanical circulatory support devices. J Heart Lung Transplant. 2013;32(2):221–30.

26. Armstrong AT, Binkley JP, Baker PB, Myerowitz PD, Leier CV. Quantitative investigation of cardiomyocyte hypertrophy and myocardial fibrosis over 6 years after cardiac transplantation. J Am Coll Cardiol. 1998;23(3):704–10.

27. Zimmer RL, Lee MS. Transplant coronary artery disease. JACC Cardiovasc Interv. 2010;3(4):367–77.

28. Haddad M, Pfugfelder PW, Guiraudon C, Novick RJ, McKenzie FN, Menakis A, Kostuk WJ. Angiographic, pathologic, and clinical relationships in coronary artery disease in cardiac allografts. J Heart Lung Transplant. 2005;24(9):1218–25.

29. St Goar GF, Pinto FJ, Alderman EL, Valantine HA, Schroeder JS, Gao SZ, Simonov EB, Popp RL. Intracoronary ultrasound in cardiac transplant recipients. In vivo evidence of “angiographically silent” intimal thickening. Circulation. 1992;85(3):979–87.

30. Huibers M, De Jonge N, Van Kuik K, Koning ES, Van Wichen D, Dullens H, Schipper M, De Weger R. Intimal fibrosis in human cardiac allograft vasculopathy. Transpl Immunol. 2011;25(1–2):124–32.

31. Yamani MH, Haji SA, Starling RC, Tuzcu EM, Ratiff NB, Cook DJ, Abdo A, Crowe T, Seic M, McCarthy P, et al. Myocardial ischemic-fibrotic injury after human heart transplantation is associated with increased progression of vasculopathy, decreased cellular rejection and poor long-term outcome. J Am Coll Cardiol. 2002;39(6):970–7.